Table 1.
Clinical and Demographic Characteristics of 2660 Military Health System Beneficiaries by SARS-CoV-2 Infection and/or Vaccination History
| Characteristic | SARS-CoV-2 Infection Alone (N = 705) | Vaccination Alone (N = 932) | Vaccine After Infection (N = 869) | Vaccine Breakthrough Infection (N = 154) | Total (N = 2660) | P Valuea |
|---|---|---|---|---|---|---|
| Vaccine | <.01 | |||||
| Pfizer/BioNTech-BNT162b2 | 727 (78.0%) | 701 (80.7%) | 134 (87.0%) | 1562 (79.9%) | ||
| Moderna/mRNA-1273 | 200 (21.5%) | 150 (17.3%) | 19 (12.3%) | 369 (18.9%) | ||
| Janssen/JNJ-78436735 | 5 (0.5%) | 18 (2.1%) | 1 (0.6%) | 24 (1.2%) | ||
| Sex | .81 | |||||
| Female | 284 (40.3%) | 390 (41.8%) | 347 (39.9%) | 60 (39.0%) | 1081 (40.6%) | |
| Male | 421 (59.7%) | 542 (58.2%) | 522 (60.1%) | 94 (61.0%) | 1579 (59.4%) | |
| Age group, years | < .01 | |||||
| 18–44 | 448 (63.5%) | 726 (77.9%) | 492 (56.6%) | 94 (61.0%) | 1760 (66.2%) | |
| 45–64 | 203 (28.8%) | 169 (18.1%) | 283 (32.6%) | 41 (26.6%) | 696 (26.2%) | |
| ≥65 | 54 (7.7%) | 37 (4.0%) | 94 (10.8%) | 19 (12.3%) | 204 (7.7%) | |
| Race/ethnicity | < .01 | |||||
| White | 314 (44.5%) | 593 (63.6%) | 468 (53.9%) | 90 (58.4%) | 1465 (55.1%) | |
| Hispanic or Latino | 200 (28.4%) | 125 (13.4%) | 192 (22.1%) | 30 (19.5%) | 547 (20.6%) | |
| Black | 102 (14.5%) | 64 (6.9%) | 109 (12.5%) | 19 (12.3%) | 294 (11.1%) | |
| Asian | 21 (3.0%) | 49 (5.3%) | 28 (3.2%) | 3 (1.9%) | 101 (3.8%) | |
| Others | 68 (9.6%) | 101 (10.8%) | 72 (8.3%) | 12 (7.8%) | 253 (9.5%) | |
| Charlson comorbidity index | < .01 | |||||
| ≥5 | 23 (3.3%) | 3 (0.3%) | 34 (3.9%) | 4 (2.6%) | 64 (2.4%) | |
| 3–4 | 28 (4.0%) | 11 (1.2%) | 44 (5.1%) | 5 (3.2%) | 88 (3.3%) | |
| 1–2 | 124 (17.6%) | 37 (4.0%) | 180 (20.7%) | 17 (11.0%) | 358 (13.5%) | |
| 0 | 530 (75.2%) | 881 (94.5%) | 611 (70.3%) | 128 (83.1%) | 2150 (80.8%) | |
| Severity | < .01 | |||||
| Inpatient | 168 (23.8%) | 142 (16.3%) | 9 (5.8%) | 319 (18.5%) | ||
| Outpatient | 537 (76.2%) | 727 (83.7%) | 145 (94.2%) | 1409 (81.5%) | ||
| Sampling timeb | ||||||
| Time since infection | 32 (20) | |||||
| Time since latest antigenic exposurec | 76 (79) | 78 (70) | 89 (63) | |||
Vaccination status determined through Military Health System Data Repository record, case report form, and/or self-report questionnaire.
a
n × k Fisher exact test.
b
Median (interquartile range).
c
Time since final dose of vaccine or infection, whatever is latest.